Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor Activity

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 185-195

  Askenasy, Nadir ^a   Mizrahi, Keren ^a   Ash, Shifra ^a   Askenasy, Enosh M ^a   Yaniv, Isaac ^a   Stein, Jerry ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Apoptosis; Donor lymphocyte infusion; Fas cross linking; Graft versus host disease; Graft versus tumor; Hematopoietic cell transplantation

Indexed keywords

CD69 ANTIGEN; FAS LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HAPLOIDY; HISTOPATHOLOGY; MOUSE; NONHUMAN; SKIN STIMULATION; STEM CELL; T CELL DEPLETION; T LYMPHOCYTE; TISSUE INJURY; TUMOR ENGRAFTMENT; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL GROWTH PROCESSES; FAS LIGAND PROTEIN; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84872621203     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.004     Document Type: Article

References (71)

1. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
2. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Gonzalez M., Quezada S.A., Blazar B.R., et al. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol 2002, 169:5581-5589.
4. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
5. Matte C.C., Liu J., Cormier J., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004, 10:987-992.
6. Anderson B.E., McNiff J.M., Jain D., et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005, 105:2227-2234.
7. Kim T.D., Terwey T.H., Zakrzewski J.L., et al. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood 2008, 111:2929-2940.
8. Matsue H., Matsue K., Kusuhara M., et al. Immunosuppressive properties of CD95L-transduced " killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 2001, 98:3465-3472.
9. Hartwig U.F., Robbers M., Wickenhauser C., Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 2002, 99:3041-3049.
10. Godfrey W.R., Krampf M.R., Taylor P.A., Blazar B.R. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004, 103:1158-1165.
11. Georgantas R.W., Bohana-Kashtan O., Civin C.I. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Transplantation 2006, 82:471-478.
12. Bohana-Kashtan O., Morisot S., Hildreth R., et al. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 2009, 183:696-705.
13. Yarkoni S., Prigozhina T.B., Slavin S., Askenasy N. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol Blood Marrow Transplant 2012, 18:523-535.
14. Prigozhina T.B., Elkin G., Khitrin S., Slavin S. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol 2004, 32:1110-1117.
15. Ju S.T., Panka D.J., Cui H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T- cell activation. Nature 1995, 373:444-448.
16. Refaeli Y., Van Parijs L., London C.A., et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998, 8:615-623.
17. Dutt S., Ermann J., Tseng D., et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005, 106:4009-4015.
18. Anderson B.E., Taylor P.A., McNiff J.M., et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 2008, 111:5242-5251.
19. Weninger W., Crowley M.A., Manjunath N., von Andrian U.H. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 2001, 194:953-966.
20. Harris N.L., Watt V., Ronchese F., Le Gros G. Differential T cell function and fate in lymph node and nonlymphoid tissues. J Exp Med 2002, 195:317-326.
21. Galkina E., Tanousis K., Preece G., et al. L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med 2003, 198:1323-1335.
22. Teshima T., Ordemann R., Reddy P., et al. Acute graft versus host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
23. Beilhack A., Schulz S., Baker J., et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008, 111:2919-2928.
24. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003, 4:154-160.
25. Na I.K., Markley J.C., Tsai J.J., et al. Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood 2010, 116:e18-e25.
26. Panoskaltsis-Mortari A., Price A., Hermanson J.R., et al. In vivo imaging of graft-versus-host-disease in mice. Blood 2004, 103:3590-3598.
27. Beilhack A., Schulz S., Baker J., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005, 106:1113-1122.
28. Silva I.A., Olkiewicz K., Askew D., et al. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation. Biol Blood Marrow Transplant 2010, 16:598-611.
29. Li B., New J.Y., Yap E.H., et al. Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease. Eur J Immunol 2001, 31:617-624.
30. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
31. + naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation. Clin Exp Immunol 2011, 165:264-277.
32. Siegel R.M., Chan F.K., Chun H.J., Lenardo M.J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000, 1:469-474.
33. McKinstry K.K., Golech S., Lee W.H., et al. Rapid default transition of CD4 T cell effectors to functional memory cells. J Exp Med 2007, 204:2199-2211.
34. Pearl-Yafe M., Stein J., Yolcu E.S., et al. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells 2007, 25:3194-3203.
35. Pearl-Yafe M., Yolcu E.S., Stein J., et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007, 35:1601-1612.
36. Ash S., Stein J., Askenasy N., Yaniv I. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft versus neurobastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer 2010, 103:1597-1605.
37. Kaminitz A., Yolcu E.S., Askenasy E.M., et al. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One 2011, 6:e21630.
38. Pearl-Yafe M., Yolcu E.S., Stein J., et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells 2007, 25:1448-1455.
39. Ash S., Gigi V., Askenasy N., et al. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 2009, 58:2073-2084.
40. Iwasaki T., Hamano T., Saheki K., et al. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells. Cell Immunol 1999, 197:30-38.
41. Marks L., Altman N.H., Podack E.R., Levy R.B. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation 2004, 77:804-812.
42. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
43. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995, 23:1553-1562.
44. Ringden O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633.
45. Kaminitz A., Askenasy E.M., Yaniv I., et al. Apoptosis of purified CD4+ T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One 2010, 5:e15684.
46. Askenasy N., Yolcu E.S., Yaniv I., Shirwan H. Fas-ligand as a double-edged immunomodulator to induce transplantation tolerance. Blood 2005, 105:1396-1404.
47. Yolcu E.S., Askenasy N., Singh N.P., et al. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002, 17:795-808.
48. Askenasy N., Yolcu E.S., Wang Z., Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003, 107:1525-1531.
49. Yolcu E.S., Gu X., Lacelle C., et al. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol 2008, 181:931-939.
50. Askenasy E.M., Shushlav Y., Sun Z., et al. Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs. Transplant Proc 2011, 43:3545-3548.
51. Franke D.D., Yolcu E.S., Alard P., et al. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 2007, 44:2884-2892.
52. Zhang Y., Joe G., Hexner E., et al. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol 2005, 174:3051-3058.
53. Zhang Y., Joe G., Hexner E., et al. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 2005, 11:1299-1305.
54. Dutt S., Tseng D., Ermann J., et al. Naive and memory T cells induce different types of graft-versus-host disease. J Immunol 2007, 179:6547-6554.
55. Zheng H., Matte-Martone C., Jain D., et al. Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J Immunol 2009, 182:5938-5948.
56. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
57. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
58. Desbarats J., Wade T., Wade W.F., Newell M.K. Dichotomy between naive and memory CD4+ T cell responses to Fas engagement. Proc Natl Acad Sci USA 1999, 96:8104-8109.
59. Inaba M., Kurasawa K., Mamura M., et al. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J Immunol 1999, 163:1315-1320.
60. Grayson J.M., Harrington L.E., Lanier J.G., et al. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol 2002, 169:3760-3770.
61. short correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signalling complex activity. J Immunol 2000, 165:6293-6300.
62. Sabbagh L., Kaech S.M., Bourbonnière M., et al. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 2004, 173:5425-5433.
63. + T cells do not induce graft-versus-host disease. J Clin Invest 2003, 112:101-108.
64. + T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004, 103:3970-3978.
65. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008, 111:2476-2484.
66. Askenasy N., Zorina T., Farkas D.L., Shalit I. Transplanted hematopoietic cells seed in clusters in recipient bone marrow in vivo. Stem Cells 2002, 20:301-310.
67. Stein J., Yaniv I., Askenasy N. Critical early events in hematopoietic cell seeding and engraftment. Folia Histochem Cytobiol 2005, 43:191-195.
68. Jiang Z., Adams G.B., Hanash A.M., et al. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002, 8:588-596.
69. Giver C.R., Li J.M., Hossain M.S., et al. Reconstructing immunity after allogeneic transplantation. Immunol Res 2004, 29:269-282.
70. Mizrahi K., Pearl-Yafe M., Stein J., et al. Regulatory functions of TRAIL in hematopoietic progenitors: murine transplants and human umbilical cord blood. Leukemia 2010, 24:1325-1334.
71. Pearl-Yafe M., Mizrahi K., Stein J., et al. TNF receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells 2010, 28:1270-1280.